These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32105674)

  • 1. Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases.
    Schiano C; Benincasa G; Franzese M; Della Mura N; Pane K; Salvatore M; Napoli C
    Pharmacol Ther; 2020 Jun; 210():107514. PubMed ID: 32105674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic-related therapeutic challenges in cardiovascular disease.
    Schiano C; Vietri MT; Grimaldi V; Picascia A; De Pascale MR; Napoli C
    Trends Pharmacol Sci; 2015 Apr; 36(4):226-35. PubMed ID: 25758254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades.
    Pourbagher-Shahri AM; Farkhondeh T; Ashrafizadeh M; Talebi M; Samargahndian S
    Biomed Pharmacother; 2021 Apr; 136():111214. PubMed ID: 33450488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients.
    Napoli C; Benincasa G; Schiano C; Salvatore M
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):239-247. PubMed ID: 31665258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target.
    Zhou H; Li N; Yuan Y; Jin YG; Guo H; Deng W; Tang QZ
    Basic Res Cardiol; 2018 Aug; 113(5):37. PubMed ID: 30094473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases.
    Altara R; Manca M; Brandão RD; Zeidan A; Booz GW; Zouein FA
    Clin Sci (Lond); 2016 Apr; 130(7):463-78. PubMed ID: 26888559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Future of Cardiovascular Therapeutics.
    MacRae CA; Roden DM; Loscalzo J
    Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in epigenetic regulation of vascular aging.
    Jin J; Liu Y; Huang L; Tan H
    Rev Cardiovasc Med; 2019 Mar; 20(1):19-25. PubMed ID: 31184092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Regulation of Autophagy in Cardiovascular Pathobiology.
    Bu S; Singh KK
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluid-based assays and precision medicine of cardiovascular diseases: the 'hope' for Pandora's box?
    Benincasa G; Mansueto G; Napoli C
    J Clin Pathol; 2019 Dec; 72(12):785-799. PubMed ID: 31611285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of redox signaling in epigenetics and cardiovascular disease.
    Kim GH; Ryan JJ; Archer SL
    Antioxid Redox Signal; 2013 May; 18(15):1920-36. PubMed ID: 23480168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Epigenetic Control and Non-coding RNAs in Cardiovascular System.
    Sharma S; Mishra A; Ashraf MZ
    Adv Exp Med Biol; 2020; 1229():121-132. PubMed ID: 32285408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergent expansion of clinical epigenetics in patients with cardiovascular diseases.
    Napoli C; Coscioni E; de Nigris F; Donatelli F
    Curr Opin Cardiol; 2021 May; 36(3):295-300. PubMed ID: 33605616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
    Chistiakov DA; Orekhov AN; Bobryshev YV
    Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioids in Cardiovascular Disease: Therapeutic Options.
    Rawal H; Patel BM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):279-291. PubMed ID: 29528698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Epigenome in Atherosclerosis.
    Costantino S; Paneni F
    Handb Exp Pharmacol; 2022; 270():511-535. PubMed ID: 33474673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.
    Xu S; Kamato D; Little PJ; Nakagawa S; Pelisek J; Jin ZG
    Pharmacol Ther; 2019 Apr; 196():15-43. PubMed ID: 30439455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics.
    Ambrosini S; Mohammed SA; Lüscher TF; Costantino S; Paneni F
    High Blood Press Cardiovasc Prev; 2020 Oct; 27(5):363-371. PubMed ID: 32740853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions.
    Bontempo P; Capasso L; De Masi L; Nebbioso A; Rigano D
    Nutrients; 2024 Jul; 16(15):. PubMed ID: 39125279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.